Laurie Alsup
Director/Board Member chez BLACKBERRY LIMITED
Fortune : 652 647 $ au 31/03/2024
Profil
Laurie Smaldone Alsup is currently an Independent Director at BlackBerry Ltd., Arvinas Operations, Inc., Theravance Biopharma, Inc., Arvinas, Inc., and NDA Group AB.
She previously served as the President & Chief Executive Officer at Phytomedics, Inc., an Independent Director at Humanigen, Inc., the Lead Independent Director at Pardes Biosciences, Inc., a Director at Kalobios Pharmaceuticals, Inc., and an Independent Director at Kinnate Biopharma, Inc. She also held the position of Senior Vice President-Global Regulatory Science at Bristol Myers Squibb Co. and the President & Chief Scientific Officer at PharmApprove LLC.
Dr. Alsup obtained her undergraduate degree from Fordham University and her doctorate from Yale School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
THERAVANCE BIOPHARMA INC
0,11% | 02/05/2023 | 53 794 ( 0,11% ) | 482 532 $ | 31/03/2024 |
ARVINAS, INC.
0,01% | 15/06/2023 | 4 121 ( 0,01% ) | 170 115 $ | 31/03/2024 |
KINNATE BIOPHARMA, INC.
-.--% | 03/04/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
BLACKBERRY LIMITED
-.--% | 29/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Laurie Alsup
| Sociétés | Poste | Début |
|---|---|---|
| BLACKBERRY LIMITED | Director/Board Member | 23/06/2015 |
| THERAVANCE BIOPHARMA, INC. | Director/Board Member | 13/02/2018 |
| ARVINAS, INC. | Director/Board Member | 20/11/2019 |
NDA Group AB
 NDA Group AB Miscellaneous Commercial ServicesCommercial Services NDA Group AB provides drug developmental consultancy services to the pharmaceutical industry. It focuses on all phases of development and therapeutic areas such as pre-submission, submission, assessment, post authorization, regulatory, pharmacovigilance, and health technology assessment. The company was founded in 1997 and is headquartered in Upplands Väsby, Sweden. | Corporate Officer/Principal | 01/08/2023 |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Director/Board Member | - |
Anciens postes connus de Laurie Alsup
| Sociétés | Poste | Fin |
|---|---|---|
| KINNATE BIOPHARMA INC. | Director/Board Member | 03/04/2024 |
| PARDES BIOSCIENCES, INC. | Director/Board Member | 30/08/2023 |
PharmApprove LLC
 PharmApprove LLC Miscellaneous Commercial ServicesCommercial Services PharmApprove LLC provides strategic regulatory and scientific communications consultancy services to the pharmaceutical and biotech industries. The firm offers both strategic and tactical support to companies facing high-profile, high stakes events and engagements anywhere along the road to approval and commercialization -including FDA Advisory Committee meetings. The company was founded by Pete Taft in 1999 and is headquartered in Lawrenceville, NJ. | President | 01/03/2016 |
| HUMANIGEN, INC. | Director/Board Member | 20/11/2015 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Laurie Alsup
| Fordham University | Undergraduate Degree |
| Yale School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BLACKBERRY LIMITED | Technology Services |
| HUMANIGEN, INC. | Health Technology |
| THERAVANCE BIOPHARMA, INC. | Health Technology |
| ARVINAS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Health Technology |
Phytomedics, Inc.
 Phytomedics, Inc. Pharmaceuticals: OtherHealth Technology Phytomedics, Inc. discovers, develops, and manufactures botanical therapeutics using proprietary platform technologies. The company was founded in December 1996 by Ilya Raskin and is headquartered in Jamesburg, NJ. | Health Technology |
NDA Group AB
NDA Group AB Miscellaneous Commercial ServicesCommercial Services NDA Group AB provides drug developmental consultancy services to the pharmaceutical industry. It focuses on all phases of development and therapeutic areas such as pre-submission, submission, assessment, post authorization, regulatory, pharmacovigilance, and health technology assessment. The company was founded in 1997 and is headquartered in Upplands Väsby, Sweden. | Commercial Services |
PharmApprove LLC
PharmApprove LLC Miscellaneous Commercial ServicesCommercial Services PharmApprove LLC provides strategic regulatory and scientific communications consultancy services to the pharmaceutical and biotech industries. The firm offers both strategic and tactical support to companies facing high-profile, high stakes events and engagements anywhere along the road to approval and commercialization -including FDA Advisory Committee meetings. The company was founded by Pete Taft in 1999 and is headquartered in Lawrenceville, NJ. | Commercial Services |
Kinnate Biopharma, Inc.
 Kinnate Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA. | Health Technology |
Pardes Biosciences, Inc.
 Pardes Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. It also focuses on developing novel drugs to solve pandemic-sized problems like the coronavirus disease. The company was founded by Uri A. Lopatin and Lee D. Arnold on February 27, 2020 and is headquartered in Carlsbad, CA. | Health Technology |
| Kalobios Pharmaceuticals, Inc. |
